Company Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma.
The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer.
Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2017 |
| IPO Date | Apr 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 47 |
| CEO | Dr. Daniel J. Hicklin Ph.D. |
Contact Details
Address: 200 Talcott Avenue, 2nd Floor Watertown, Massachusetts 02472 United States | |
| Phone | 617-952-0555 |
| Website | werewolftx.com |
Stock Details
| Ticker Symbol | HOWL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001785530 |
| CUSIP Number | 95075A107 |
| ISIN Number | US95075A1079 |
| Employer ID | 82-3523180 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel J. Hicklin Ph.D. | Founder, Chief Executive Officer, President, Secretary and Director |
| Dr. Randi Isaacs M.D. | Chief Medical Officer |
| Timothy W. Trost CPA | Chief Financial Officer, Treasurer and Assistant Secretary |
| Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer |
| Ellen A. Lubman M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | ARS | Filing |
| Apr 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 12, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 7, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 7, 2024 | 10-K | Annual Report |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |